Ipilimumab plus nivolumab for advanced melanoma
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 8, 2016
|
| In: |
The lancet. Oncology
Year: 2016, Jahrgang: 17, Heft: 11, Pages: 1471-1472 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(16)30409-0 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(16)30409-0 Verlag, Volltext: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30409-0/abstract 
|
| Verfasserangaben: | Jessica C. Hassel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1564755754 | ||
| 003 | DE-627 | ||
| 005 | 20220814010949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171025s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(16)30409-0 |2 doi | |
| 035 | |a (DE-627)1564755754 | ||
| 035 | |a (DE-576)49475575X | ||
| 035 | |a (DE-599)BSZ49475575X | ||
| 035 | |a (OCoLC)1340980920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 245 | 1 | 0 | |a Ipilimumab plus nivolumab for advanced melanoma |c Jessica C. Hassel |
| 264 | 1 | |c September 8, 2016 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.10.2017 | ||
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 17(2016), 11, Seite 1471-1472 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Ipilimumab plus nivolumab for advanced melanoma |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:11 |g pages:1471-1472 |g extent:2 |a Ipilimumab plus nivolumab for advanced melanoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(16)30409-0 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30409-0/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171025 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1564755754 |e 2986024254 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1564755754","physDesc":[{"extent":"2 S."}],"title":[{"title_sort":"Ipilimumab plus nivolumab for advanced melanoma","title":"Ipilimumab plus nivolumab for advanced melanoma"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 25.10.2017"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"September 8, 2016"}],"person":[{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."}],"relHost":[{"note":["Gesehen am 22.09.2021"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"title":[{"partname":"Oncology","title_sort":"lancet","title":"The lancet"}],"origin":[{"publisher":"The Lancet Publ. Group","publisherPlace":"London","dateIssuedKey":"2000","dateIssuedDisp":"2000-"}],"disp":"Ipilimumab plus nivolumab for advanced melanomaThe lancet. Oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"325349770","part":{"year":"2016","volume":"17","pages":"1471-1472","extent":"2","text":"17(2016), 11, Seite 1471-1472","issue":"11"},"id":{"zdb":["2035574-9"],"issn":["1474-5488"],"eki":["325349770"]},"titleAlt":[{"title":"The lancet <London> / Oncology"}],"pubHistory":["0.2000 -"]}],"id":{"eki":["1564755754"],"doi":["10.1016/S1470-2045(16)30409-0"]},"name":{"displayForm":["Jessica C. Hassel"]}} | ||
| SRT | |a HASSELJESSIPILIMUMAB8201 | ||